The impact of underlying disease state on outcomes in patients with pyoderma gangrenosum: A national survey - 19/09/18
, Alice Hinton, PhD b, Somashekar G. Krishna, MD, MPH cAbstract |
Background |
Whether the underlying disease affects the outcomes in pyoderma gangrenosum (PG) is unclear.
Objectives |
To determine the impact of comorbid disease associations and concomitant procedural treatments on patient outcomes in hospitalizations of patients with PG.
Methods |
A cross-sectional analysis of the National Inpatient Sample for hospitalizations of patients with PG from the years 2002 to 2011, analyzing in-hospital mortality rate and health care resource utilization.
Results |
Inflammatory bowel disease was the most frequent comorbid association, followed by inflammatory arthritis, hematologic malignancies/dyscrasia, and vasculitis. Multivariable modeling showed that vasculitis and hematologic malignancy/dyscrasia, when compared with inflammatory bowel disease, were associated with a 4-fold to 6-fold increased risk of in-hospital mortality and increasing health care resource utilization. Inpatient procedural interventions, including skin grafts, biopsies, and debridement, did not affect mortality and were associated with an increased length of stay.
Limitations |
The database does not account for outpatient follow-up; additionally, there was a low rate of coded comorbid conditions.
Conclusions |
Comprehensive evaluation to determine the underlying comorbidity for patients with PG is important for patient risk stratification.
Le texte complet de cet article est disponible en PDF.Key words : biopsy, Crohn's disease, debridement, hospital, inflammatory bowel disease, mortality, neutrophilic disease, pyoderma gangrenosum, rheumatoid arthritis, ulcerative colitis, utilization, vasculitis
Abbreviations used : CI, IA, IBD, LOS, OR, PG
Plan
| Funding sources: Supported in part a National Institutes of Health, National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award (grant UL1TR001070). |
|
| Disclosure: Dr Kaffenberger is an investigator for Biogen, Celgene, Eli Lilly, and XBiotech. Drs Hinton and Krishna have no conflicts of interest to disclose. |
|
| The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
| Reprints not available from the authors. |
Vol 79 - N° 4
P. 659 - octobre 2018 Retour au numéro
Article précédent
- Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: Real-world data from a nationwide cohort study in Taiwan
- Kuo-Tung Tang, Yi-Ming Chen, Shih-Ni Chang, Ching-Heng Lin, Der-Yuan Chen
- Epidemiology of pediatric nickel sensitivity: Retrospective review of North American Contact Dermatitis Group (NACDG) data 1994-2014
- Erin M. Warshaw, Kelly A. Aschenbeck, Joel G. DeKoven, Howard I. Maibach, James S. Taylor, Denis Sasseville, Donald V. Belsito, Joseph F. Fowler, Kathryn A. Zug, Matthew J. Zirwas, Anthony F. Fransway, Vincent A. DeLeo, James G. Marks, Melanie D. Pratt, Toby Mathias
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?